Navigation Links
Nexavar Significantly Extends Overall Survival by 44% in Liver,Cancer Patients

2, VEGFR-3, PDGFR-B, KIT, FLT-3 and RET. Preclinical models have also demonstrated that the Raf/MEK/ERK pathway has a role in HCC; therefore blocking signaling through Raf-1 may offer therapeutic benefits in HCC.

Nexavar is currently approved in more than 50 countries, including the United States and those in the European Union, for the treatment of patients with advanced kidney cancer. In Europe, Nexavar is approved for the treatment of patients with advanced renal cell carcinoma (RCC) who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy. Nexavar is also being evaluated by the companies, international study groups, government agencies and/or individual investigators as a single agent or combination treatment in a wide range of other cancers, including adjuvant therapy for kidney cancer, metastatic melanoma, breast cancer and non-small cell lung cancer (NSCLC). The Phase 3 ESCAPE (Evaluation of sorafenib, carboplatin, and paclitaxel efficacy in NSCLC) trial recently completed enrollment of more than 900 previously untreated patients with NSCLC of all histologies.

"HCC is the second tumor type in which Nexavar has demonstrated a clinical benefit. We intend to move swiftly with our partner Onyx to file these data for health authority review," said Susan Kelley, MD, Vice President, Therapeutic Area Oncology, Bayer HealthCare Pharmaceuticals. "Our strategy of leveraging the unique attributes of Nexavar, the only approved orally administered anti-angiogenic that targets the Raf pathway, has led to a robust ongoing clinical program that could bring the potent cancer fighting properties of this oral multi-kinase inhibitor to an even broader number of patients in the coming years."

Important Safety Considerations for U.S. Patients Taking Nexavar

Based on the currently approved package insert for the treatment of patients with advanced kidney cancer, hypertension may occur early in the
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Review of Nexavar Data Presented at ASCO 2007- Investor Conference Call on June 4, 2007
2. Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Womens Health Initiative Data
3. Prexige Study Shows Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
4. Lumiracoxib Study Showed Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
5. Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid Arthritis Compared to a Current Standard of Care
6. Next Safety, Inc.s Innovative Drug Delivery System Will Replace Cigarettes and Significantly Advance Pulmonary Medication Delivery
7. Ivivis PEMF Technology Significantly Improves Neuron Survival in Parkinsons Disease Model, Study Finds
8. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
9. The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved Progression Free Survival When Given Before and After Surgery in Patients With Resectable Liver Metastases From Colorectal Cancer
10. MabThera Significantly Extends Survival And Cures More Patients With Aggressive Lymphoma Than Chemotherapy Alone
11. Breaking Multi-Center Study: Masimo SET Pulse Oximetry Technology Shown to Significantly Lower Instances of Severe Retinopathy of Prematurity in Extremely Low Birth Weight Infants
Post Your Comments:
(Date:5/24/2013)... CHESTERBROOK, Pa. , May 24, 2013  Auxilium ... that executive management will participate in the Deutsche Bank ... the Westin Boston Waterfront Hotel.  Mr. Adrian ... scheduled to present an overview of the Company and ... May 29, 2013.   (Logo: http://photos.prnewswire.com/prnh/20101202/MM10881LOGO ...
(Date:5/24/2013)... BEIJING , May 24, 2013  Sinovac ... leading provider of biopharmaceutical products in ... main operating subsidiary company of Sinovac, obtained the ... (GMP Certificate) from the China State and Food ... district bulk production plants, and its Changping filing ...
(Date:5/24/2013)... England and BOSTON , May 24, ... discovery and development company, is pleased to announce that it has ... to augment the Company,s business development capabilities in Japan ... more than 15 years of experience in business development, licensing and ... Sciences, Inc., Roche Pharma ( Japan ), Nippon Roche ...
Breaking Medicine Technology:Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 2Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 3Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 4Sinovac Beijing Obtains China GMP Certificate Under the New GMP Guidelines 2Sinovac Beijing Obtains China GMP Certificate Under the New GMP Guidelines 3Heptares Augments Business Development Capabilities in Japan and Other Asian Territories 2
... MERCER ISLAND, Wash., Dec. 22, 2010 Renal Advantage and ... the third largest provider of dialysis services in the U.S., ... – terms of which were not disclosed – was completed ... serving more than 19,000 patients in 260 locations in 32 ...
... AstraZeneca (NYSE: AZN ... will discontinue the development of CERTRIAD™ (rosuvastatin calcium and fenofibric ... dyslipidemia. This means the co-development and license agreement with Abbott ... Complete Response Letter (CRL) for the CERTRIAD New Drug Application ...
Cached Medicine Technology:Renal Advantage and Liberty Dialysis Deal Completed 2Renal Advantage and Liberty Dialysis Deal Completed 3
(Date:5/25/2013)... (PRWEB) May 25, 2013 Actos ... underway in U.S. District Court, Western District of Louisiana, ... According to a Case Management Order issued on May ... filing of contested motions in the Actos bladder cancer ... (In re: Actos Product Liability Litigation, MDL No. 2299) ...
(Date:5/25/2013)... great companions for senior citizens, but elderly people who always ... likely to crash than those who never drive with a ... licensed drivers aged 70 and older. The nearly 700 participants ... their pet in the car. Among those who always ... high as among those who never drove with their pet. ...
(Date:5/25/2013)... May 25, 2013 Radius Engineering ... shelter company in the US and has been ... for over 35 years. M.E. and President, Walton ... of NBC Weapon Fundamentals and Shelter Engineering Standards, ... bible on shelter engineering. McCarthy is considered the ...
(Date:5/25/2013)... 2013 Providing patients with their best weight ... of weight management professionals. But, aside from educating patients on ... Doc’s hCG diets also provide patients, who have ... like bullying, more control over their lives by achieving their ... the underlying factors of weight gain derived from earlier abuse, ...
(Date:5/25/2013)... New York, NY (PRWEB) May 25, 2013 ... reported that many people do not wish to discuss or ... responsibility in life. FuneralFinancials.com released a Must-Do ... , 1. Funeral Financials recommends, “Creating a personal fact ... be used to organize financial information and personal data. ...
Breaking Medicine News(10 mins):Health News:Actos Lawsuit News: Bernstein Liebhard LLP Notes New Case Management Order in Federal Actos Bladder Cancer Litigation 2Health News:Actos Lawsuit News: Bernstein Liebhard LLP Notes New Case Management Order in Federal Actos Bladder Cancer Litigation 3Health News:Seniors More Likely to Crash When Driving With Pet: Study 2Health News:Radius Engineering International Inc. Offers Tools to Stay Safe and Recover From Any Disaster 2Health News:Radius Engineering International Inc. Offers Tools to Stay Safe and Recover From Any Disaster 3Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announces hCG Diet Plans for Those Suffering from Abuse-Related Weight Gain 2Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announces hCG Diet Plans for Those Suffering from Abuse-Related Weight Gain 3Health News:FuneralFinancials.com Releases Last Wishes Must-Do List 2
... to the heart improves as one watches more comedy films, ... Researchers asked 20 healthy young adults to watch 15 to ... of 48 hours apart. // ,Participants were ... or taking aerobic exercise the evening before the experiment, as ...
... can be detected through measuring a certain protein present in ... reported to be the fifth most malignant, which recorded 63,210 ... 13,000 deaths. The country has a total of 500,000 patients ... recurrence is between 50% and 90%. ,There ...
... US health insurers who are under contract with the new ... Administration to be in a position to make 30 day ... as several patients // across the country were reportedly unable ... the responsibility of insurers to ensure that an amount of ...
... very upset and has sent a letter to the acting head ... his letter he had asked the FDA to provide a full ... was reveled that the tainted tissues were used for the patients ... probe into the matter about the case of the Brooklyn funeral ...
... Bird flu pandemic is on the rise as there are ... Haemagglutinin antigen fragment of the bird flu virus and there ... by these viruses. Scientists are working out plans of Passive ... of the infected bird flu patient, the antibody is produced ...
... plague has hit Western Australia's south region with 50 cases ... River virus has also been // reported in the Territories ... days. ,Entomologist Nina Kurucz said that the pre-monsoon ... "The problem is that this sort of mosquito can fly ...
Cached Medicine News:
Highly concentrated daily cleaner with Microclens beads for superior cleaning action....
Round knurled handle. Overall length 130 mm....
... contact lens cleaning solution is ... and professionally proven cleaner. A ... resulting in a very effective ... cosmetic residue, salts, mucous and ...
Optimum C/D/S Solution is a sterile cleaning, disinfecting, and storage solution for use with fluorosilicone acrylate and silicone acrylate rigid gas permeable (RGP) and hard contact lenses....
Medicine Products: